On Monday, the American Academy of Neurology released preliminary data from the drug’s open label testing stage, a precursor to the controlled double-blind scientific trials currently underway. The research revealed that more than 50 percent of the 137 epileptic children and young adults continually treated with Epidiolex over a period of three months saw a reduction in their seizures.
As Reported by: Huffington Post
http://www.huffingtonpost.com/2015/04/13/epidiolex_n_7055784.html
